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Abstract
Background: Lung cancer is the commonest cause of cancer death in developed countries.
Adenocarcinoma is becoming the most common form of lung cancer. Cigarette smoking is the main
risk factor for lung cancer. Long-term cigarettes smoking may be characterized by genetic
alteration and diffuse injury of the airways surface, named field cancerization, while cancer in non-
smokers is usually clonally derived. Detecting specific genes expression changes in non-cancerous
lung in smokers with adenocarcinoma may give us instrument for predicting smokers who are going
to develop this malignancy.
Objectives: We described the gene expression in non-cancerous lungs from 21 smoker patients
with lung adenocarcinoma and compare it to gene expression in non-cancerous lung tissue from
10 non-smokers with primary lung adenocarcinoma.
Methods: Total RNA was isolated from peripheral non-cancerous lung tissue. The cDNA was
hybridized to the U133A GeneChip array. Hierarchical clustering analysis on genes obtained from
smokers and non-smokers, after subtracting were exported to the Ingenuity Pathway Analysis
software for further analysis.
Results: The genes subtraction resulted in disclosure of 36 genes with high score. They were
subsequently mapped and sorted based on location, cellular components, and biochemical activity.
The gene functional analysis disclosed 20 genes, which are involved in cancer process (P = 7.05E-5
to 2.92E-2).
Conclusion: Detected genes may serve as a predictor for smokers who may be at high risk of
developing lung cancer. In addition, since these genes originating from non-cancerous lung, which
is the major area of the lungs, a sample from an induced sputum may represent it.
Background
Lung cancer is the commonest cause of cancer death in
developed countries and throughout the world. World-
wide, the estimated number of new lung cancer cases in
2002 is 1.2 million (12.3% of all new cancer cases). Over
90% of these new cases will die as a result of the disease
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[1]. The death rate for lung cancer exceeds the combined
total for breast, prostate and colon cancer in developed
countries [1]. Cigarette smoking is the main risk factor for
lung cancer, accounting for about 90% of cases in men
and 70–85% of cases in women [2]. Genetic risk factors
contribute to an individual's susceptibility to lung cancer,
which is illustrated by the fact that about 16% of long-
term smokers will develop lung cancer [3]. Unfortunately,
no effective clinical tests are available for early detection
of lung cancer. Smoking cessation programs are critical,
but ex-smokers continue to have a higher risk to develop
lung cancer. Even more than 40 years after cessation com-
pared with never-smokers [4]. These days ex-smokers
comprise almost 50% of all new lung cancer cases in
developed countries, indicating a strong need for a search
for new means of early diagnosis in lung cancer and che-
moprevention in this high-risk group (4). Nevertheless,
an important issue for these approaches is the appropriate
selection of an optimal high-risk population.
Long-term carcinogenic exposure (cigarettes smoke) is
characterized by genetic alteration and diffuse injury of
the airways surface [5]. These changes in epithelium can
give rise to cancer at multiple points, for that reason
named field cancerization. Genetic changes detected in
premalignant lesions or malignant in one region of the
field, translate into an increased risk of cancer develop-
ment throughout the entire field. Therefore, it can be con-
cluded that cigarettes smoking may induce field
cancerization whereas cancer in non-smokers is clonally
derived, i.e. by single cell transformed is the ancestor of all
cells that compose the neoplasm [6-8].
The consequence of this is that the non-cancerous tissue
in non-smoker patient with primary lung cancer should
not show any alteration compared to normal, whereas in
smokers due to field cancerization morphological and
genetic alteration may possibly be observed. Probably,
this genetic alteration in smokers could serve for early
detection of lung cancer.
Identification of individuals at greatest risk of developing
lung cancer could enhance the efficacy of intervention
modalities, thereby greatly reducing mortality from this
disease. One strategy for identifying these people is to
establish molecular markers that reflect the severity of
their cancerization field.
Microarray can simultaneously measure the expression of
thousands of mRNAs. They are used in many biological
fields and in different species. This high-throughput tech-
nique can be used to predict the function of unknown
genes, in medical diagnostics, in biomarker discovery, to
infer networks from the regulatory interactions between
genes, and to investigate the mechanisms by which a drug,
disease, mutation and environmental condition affects
gene expression and cell function. Large datasets are pro-
duced, particularly from whole-genome arrays, and public
databases hold substantial quantities of gene-expression
information [9,10].
Adenocarcinoma (AC) is becoming the most common
form of lung cancer. It has increased relative to other his-
tological types of lung cancer over the last several decades
[11-14].
These observations lead us to investigate the gene expres-
sion in non-involved lungs from patients with adenocar-
cinoma and compare it to gene expression in non-
involved lung tissue from non-smokers. We used the
U133A GeneChip array (Affymetrix, Santa Clara, CA),
GeneSpring analysis software and the Ingenuity Pathway
Analysis software.
Methods
Patient Lung Tissue Samples
We obtained lungs tissue from 32 patients with adenocar-
cinoma of lung who underwent pulmonary lobectomy
(Table 1). All were pre-operatively diagnosed as having
lung adenocarcinoma by bronchoscopy or fine needle
aspiration. Tumors were carefully staged preoperatively,
and clinically believed to be N2 node negative by, compu-
terized tomography, positron emission tomography, or
more frequently mediastinoscopy. None of the patients
received preoperative anti-cancer therapy. Surgery
included mediastinal lymph node sampling. The histo-
logical classification was made according to the standard
WHO criteria. The affected lobes were removed; all non-
involved lung tissue samples were obtained in accordance
with Institutional Review Board guidelines. The tissues
were carefully inspected, and declared histologically nor-
mal (never-smokers) or non-cancerous (smokers).
RNA isolation and microarray hybridization
RNA isolation and microarray hybridization. Total RNA
was isolated from lung cancer tumor tissue and adjacent
non cancerous lung tissue using RNeasy midi kit (Qiagen
sciences Maryland USA). cDNA was synthesized from 8 ug
total RNA using the SuperScript double stranded cDNA
synthesis kit (Invitrogen, Carlsbad CA, USA), and T7-
oligo(dT)24  primer, according to the manufacturer's
instructions. Biotynilated cRNA was synthesized using the
"ENZO bioarray high yield RNA transcript labeling kit".
(Enzo life sciences Inc., Farmingdale NY USA). The frag-
mented probe was hybridized to the Affymetrix Human
genome U133A Genechip, according to the manufac-
turer's protocol (Affymetrix inc. Santa Clara, CA USA).
The microarrays were scanned using a confocal scanner
(Affymetrix Inc.). 18S ribosomal RNA was used as an
endogenous control. A single weighted mean expressionJournal of Experimental & Clinical Cancer Research 2008, 27:45 http://www.jeccr.com/content/27/1/45
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level for each gene was derived by using Microarray Suite
5.0 software (Affymetrix).
GeneSpring hierarchical clustering analysis
Expression data were normalized using GeneSpring 7.0
software (Silicon Genetics inc. Redwood CA USA). Gene
expression data were normalized in 2 steps. (1) Per chip
normalization: and (2) Per gene normalization. We com-
pared gene expression originating from normal lung to
non-cancerous lung. More than three fold in expression
were considered as significant and used for further analy-
sis.
RT-PCR
The seven genes (FYN, MYCN, BRCA1, CD44, Cyclin B2,
CDK5RAP3 and RAGE), were further analyzed using
quantitative RT-PCR. Cancerous and non cancerous lung
tissues from eight randomly chosen patients were studied.
1st strand cDNA was synthesized from 2 ug total RNA by
random priming, using the Superscript II cDNA synthesis
kit (Invitrogen, Carlsbad CA, USA) according to the man-
ufacturer's instructions. RT PCR reactions were carried out
using Taq-Man "Assay on demand" gene expression prim-
ers and probe sets; results were analysed by GeneAmp
5700 SDS software (Applied Biosystems, Branchburg, NJ
USA). The assays used were: FYN- PPH00147A_ml,
MYCN- PPH10927A_ml, BRCA1- PPH00322B_ml,
CD44- PPH00114A_ml, RAGE – Hs0015395_m1, Cyclin
B2 – Hs00270424_m1 and CDK5RAP3 –
Hs01003183_g1. 18S ribosomal RNA was used as an
endogenous control. (Hs99999901_s1). The RT-PCR
results were analyzed using the comparative threshold
cycle (CT) method. The "relative Quantity" (RQ) of each
gene was calculated as follows: RQ =  . (15)
Ingenuity Pathway analysis
A network pathway is initiated by the gene with the high-
est specificity of connections, and is propagated according
to the descent of the specificity. Individual significant
pathways identified by a statistical likelihood calculation
2
−ΔΔCT
Table 1: Profile of Lung adenocarcinoma patients
Age/gender Smoker *FEV1% Tumor size (mm) Lymph node Stage
80/M Yes 55 25 T 1N 0 I a
76/M Yes 72 30 T 1N 0 I a
70/F Yes 48 24 T 1N 0 I a
58/M Yes 82 22 T 1N 0 I a
62/M Yes 35 28 T 1N 0 I a
54/M Yes 45 24 T 1N 0 I a
74/F Yes 85 32 T 2N 0 I b
60/M Yes 80 20 T 1N 0 I a
68/F Yes 88 25 T 1N 0 I a
74/F Yes 76 30 T 1N 0 I a
65/F Yes 82 15 T 1N 0 I a
72/M Yes 88 35 T 2N 0 I b
54/M Yes 45 40 T 2N 0 I b
62/M Yes 72 40 T 2N 0 I b
64/M Yes 62 35 T 2N 0 I b
78/F Yes 78 45 T 2N 0 I b
45/M Yes 72 35 T 2N 0 I b
54/M Yes 46 35 T 2N 0 I b
75/M Yes 72 35 T 2N 0 I b
73/F Yes 72 75 T 2N 0 I b
72/M Yes 56 35 T 2N 1 II b
54/M No 85 18 T 1N 0 I a
68/F No 106 15 T 1N 0 I a
68/F No 106 15 T 1N 0 I a
68/F No 100 25 T 1N 0 I a
72/M No 104 37 T 2N 0 I b
78/F No 112 45 T 2N 0 I b
79/F No 96 40 T 2N 0 I b
68/M No 84 35 T 2N 0 I b
85/M No 90 35 T 2N 0 I b
78/F No 96 24 T 1N 1 II a
* = % of predicted
FEV1 = forced expiratory volume in first secondJournal of Experimental & Clinical Cancer Research 2008, 27:45 http://www.jeccr.com/content/27/1/45
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(P < 0.0001) were merged to represent the biological proc-
esses. The Ingenuity Pathways Knowledge Base (KB) is the
largest curetted database of previously published findings
on mammalian biology from the public literature (Inge-
nuity Systems). Reports on individual studies of genes in
human, mouse or rat were first identified from peer-
reviewed publications, and findings were then encoded
into ontology by content and modeling experts. Manual
extraction and curation probably results in more specific
and comprehensive interactions, with far fewer false-pos-
itives than automated alternatives (for example, natural
language processing and high-throughput screening).
Identification of significant pathways in biological proc-
esses: The following steps were used: (1) Genes identified
as significant from the experimental data sets were over-
laid onto the interactome. Focus genes were identified as
the subset having direct interaction(s) with other genes in
the database. (2) The specificity of connections for each
focus gene was calculated by the percentage of its connec-
tions to other significant genes. The initiation and growth
of pathways proceeded from genes with the highest specif-
icity of connections. Each pathway had a maximum of 35
genes. (3) Pathways of highly interconnected genes were
identified by statistical likelihood using the following
equation:
Where N is the number of genes in the genomic network,
of which G are focus genes, for a pathway of s genes, f of
which are focus genes. C(n,k) is the binomial coefficient.
(4) Pathways with a score greater than 4 (P < 0.0001) were
combined to form a composite network representing the
underlying biology of the process.
Network and gene ontology analysis
The genes, which were most differentially expressed
between smokers and non – smokers, were used for net-
work and gene ontology analysis. These genes were
exported to the Ingenuity Pathway Analysis (IPA) software
(Ingenuity Systems, Mountain View, CA). Of the 36 genes,
35 were mapped and sorted based on location, cellular
components, and reported or suggested biochemical, bio-
logic, and molecular functions using the software http://
www.ingenuity.com. The identified genes also were
mapped to genetic networks available in the Ingenuity
database and then ranked by score. The score is the prob-
ability that a collection of genes equal to or greater than
the number in a network could be achieved by chance
alone. A score of 3 indicate that there is 1/1000 chance
that the focus genes are in a network due to random
chance. Therefore, score of 3 or higher have a 99.9% con-
fidence level of not being generated by random chance
alone. It is possible for a pathway to be both up-regulated
and down-regulated, perhaps because of a block in the
pathway where genes above and below the block respond
differently. Visualizing the results on pathways will assist
the identification of genes that are missing from a path-
way.
Results
The clinical profile of the patients is shown in Table 1.
This includes patients' pulmonary function data, which
showed that 12 smokers had chronic obstructive pulmo-
nary disease (COPD)(FEV1 < 75%), whereas none of the
non-smokers own this limitation. GeneSpring hierarchi-
cal clustering was applied to gene expression profiles. We
subtracted highly expressed genes of non-smokers from
smokers this disclosed 36 genes that were expressed differ-
ently between smoker and non-smokers. The Ingenuity
analysis and sorting of the 36 genes according theirs
expression (bolded and italic over-expressed) or sup-
pressed (normal) while forming networks (Table 2). The
first network includes very high scored and focus genes,
which are involved in cell death, cancer and inflammatory
processes. The following networks with lower score (but
still high) and focus genes, included genes that are
involved in cellular assembly and organization, cellular
function and maintenance. The illustrated network (Fig.
1) (serve as a paradigm) demonstrates the intensity of
genes over-expressed (red) or suppressed (green) in smok-
ers compared to non-smokers, and their genes network
formation. The network includes genes that are cancer
promoters and tumor suppressors such as FYN HSPA8,
YWHAZ, LEPR and TGFBR2, IRF2, EP3000 respectively.
The suppression of the genes EGR1 and STAT1 correlates
with active tumor formation. Many networks include
fewer genes in spite of being scored high. This is probably
due to lack of knowledge.
The gene ontology analysis using the IPA tool showed that
many functions were identified as high-level functions
(Table 3). Fischer's exact test was used to calculate a p-
value determining the probability that each biological
function and/or disease assigned to that data set is due to
chance alone. Of these, twenty genes were revealed as
involved in cancer process (P = 7.05E-5 to 2.92E-2).
Discussion
Tumorigenesis is a multistep process characterized by a
myriad of genetic and epigenetic alterations. The evolu-
tion of human cells is driven by the aberrant function of
genes that positively and negatively regulate various
aspects of the cancer phenotype, including altered
responses to mitogenic and cytostatic signals, resistance to
programmed cell death, immortalization, neo-angiogen-
esis, and invasion and metastasis. Therefore identification
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of individuals at greatest risk of developing lung cancer at
the initial steps of cancer development could enhance the
efficacy of intervention modalities, thereby greatly reduc-
ing mortality from this disease.
We compared gene expression profiles of non-malignant
lung tissue from patients with AC, smokers and non-
smokers, matched for clinical staging all were at stage 1
besides 1 from each group at stage 2 and histologically
had well differentiated adenocarcinoma. One can argue
why not using matched smokers as control to those who
developed already lung cancer? Both have the same risk
factor to develop lung cancer but this doesn't preclude
future lung cancer in the control group. Therefore they
weren't useful for detection of markers for developing
lung cancer in smokers.
Thirty six genes were differently expressed in smokers
non-cancerous lung tissue compared to same tissue of
non-smokers. Many of these genes are involved in the can-
cer process as described above. Smoking is the major risk
factor for developing lung cancer but also it is a major risk
factor for COPD, which is a diffuse pulmonary inflamma-
tory and obstructive lung disease. Furthermore, it is an
established fact that airflow obstruction, measured by
simple spirometry, is an independent risk factor for the
development of lung cancer. Some studies [15,16] have
reported an increased risk of four to six times that of
patients without airflow obstruction. The exact mecha-
nism of the impact of COPD on the development of lung
cancer is unknown [17]. A better genes isolation by addi-
tion of control groups from smokers only or COPD
patients lung may be hampered by the fact that they may
contain cells in precancerous or even cancerous changes,
and various degree of inflammation. We also initially
examined 4 patients with metastatic colon adenocarci-
noma. Since their gene expression was different from lung
adenocarcinoma as expected, it was stopped due to lack of
relevance.
This study was based on the observation that in smokers,
even the non-cancerous tissue demonstrates widespread
morphological changes and tumors may arise within the
genetically abnormal cells [18]. In contrast, adenocarci-
noma in nonsmokers more likely arises in a field of rela-
tively normal cells, as might be the case with prior
infection, such as seen in "scar carcinomas."
As mentioned smoking induce changes of variable magni-
tude to the airways epithelia. Some of these subjects
Table 2: Genes in networks
Network Genes in Network Score Focus Genes Top function
1 AIP, ATF2, BTK, CASBAP2, CD44, EEF1A1, EGR1, EP300, 
EPHA2, TF21, HMGB1, HSPA8, HSPCB, IRF2, IRS4, 
KIAA0853, LEPR, MAP2K3, NFYB, NPM1, NR3C1, P8, 
PCTK2, PECAM1, PSME3, PTPN11, RDX, SNX2, STAT*, 
TGFBR2, TNFRSF6, YWHAZ*, YY1
51 35 Cell death, Cancer, Inflammatory diseases
2 CCT2, CD3Z, CDK2, COL6A1, COL6A2, COL6A3, EIF5, 
EWSR1, FCGR3B, FGF2, FGFBP1, FMR1, FUSIP1, GNA11, 
GNA13, GNB1, INPP5E, M11S1*, MAPKAP1, Pkci, PPR1R12A, 
PRKCZ, RAI14, RBM4, RGS13, RMOQ, SFN*, SKP1A, SQSTM1, 
STX4A, SYPL, UBE2A, VAMP2, VAPA, YWHAG
26 31 Cellular assembly and organization, Cellular 
function and maintenance, Cell signaling
3 ATF2, C19orf2, DHX9, DR1, RBLN1, FHL1*, FN1, HBA1, HBA2, 
HBB*, HBE1, HBG1, HBG2, HBZ, HHEX, HMGB1, HNRPA1, 
HNRPC, IL6, LRPPRC, MTPN, NRP1, PAPOLA, POLR2A, 
POLR2F, RBPSUH, REL, RNU2, RPS25, SMARCB1, 
SNAPC2, TBP, TCF21, TNXB, VEGFB
18 19 Cell to cell signaling and interaction. Cell 
morphology.
4 ADAB1*, AK2, ALCAM, AQP1, CDC2, CDKN2A, CLU, CDP, 
FOS, GD12, MIF, MYBL2, MYC, MYCN, PRDX1, PRDX2, 
PRKACB, PRKARIB, RBMS1, RPL7A, RPS16, SUMO2, TPM1, 
TXN, UNR
15 15 Cellular growth and proliferation, cellular 
and connective tissue development
5 CCL20, CD44, CDC2, CEPBP, CXCL1, FOS, G3BP2, ICAM1, 
KIAA0992, MCF2, MET, MGAT4A, MTPN, NFKB1, NFKB1B, 
NR3C1, OK/SW-cl.56, PSMA7, RDX, RELA, RHOC, RPS24, 
SCAMP1, SMARCA4, SNAP23, STAT1*, STX4A, STX6, 
TLR2, TNF, TRA1*, TUBA6, VAMP3*, VIL2, WASF2
15 17 Cell death, Immunological disease
6 ALDH1A1, ANXA2, BRAF, BRCA1, CCNB1, CDK4, 
CDKN2A, DDA3, DHX9, HMGA1, IDI1, IPO7, KPNA4, 
KPNB1, LMO4, MMP2, MYCN, MMI, NPM1, RASGRP1, 
RBBPS, RPL12, RPL19, RPL23A, RPL3, RPL31, RPL37A, RPL39, 
RPL5, RPLPO, RPS2, SFN*, TBX2*, TP73, TP73L
15 17 Cancer, Cell morphology, Cellular 
development
Genes in bold and italic – over-expressed, small font – suppressed.
*- genes appearing in more than in one network.Journal of Experimental & Clinical Cancer Research 2008, 27:45 http://www.jeccr.com/content/27/1/45
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develop COPD, some develop lung cancer, and some
both. RNA gene expression might be changed by all the
described above. In addition, the presence of tumor itself
may induce some inflammatory changes i.e. genes
changes. The variety of genes obtained represent specific
changes occurring in lung of smokers who develop AC of
Gene network is from IPA analysis Figure 1
Gene network is from IPA analysis. Gene interaction is shown, red colored up-regulated, green colored suppressed. 
Color intensity is relative to expression. Genes along canonical pathways that were not changed at transcript level are not 
colored. The arrow pointed toward the direction of positive regulation.Journal of Experimental & Clinical Cancer Research 2008, 27:45 http://www.jeccr.com/content/27/1/45
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lung. It should be emphasized that the so called field can-
cerization may not always develop lung cancer and there-
fore these changes are not a one way road. Since the
inflammatory and cancer development are a dynamic
processes the genes in the network may change their state
of expression, to be precise their activity. A biological pro-
gression model can be postulated in which field develop-
ment plays a central role and its network gene expression
change reciprocally. Consequently, monitoring of field
may have profound implications for cancer detection and
prevention. In view of the fact that detection of lung can-
cer in early state provide a better prognosis it's One of the
major objective to early detect lung cancer is sampling of
the suspected material. Usually the most convenient
materials are those originated from blood or sputum
because of simple to obtain. The value of genes expression
changes and their location in biological networks, may
serve as a warning for smokers and ex-smokers for the
higher risk of developing lung cancer, i.e. early detection
of lung cancer. Since these changes are as described field
distributed the sampling could be regional rather than
focal. Therefore, sputum sample cells may represent cells
within the "field" and altered with genetic precancerous
changes.
Conclusion
We described 36 genes that may represent the responsible
genes for enhanced risk for developing lung cancer in
smokers. The relatively small sample size may contribute
to reduced power of the study results. Movement towards
the development of consortia to pool findings across stud-
ies and increase sample size and power will address some
of this issue.
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